Skip to main content
All lobbying filings

COVINGTON & BURLING LLP

Lobbying for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · $170,000.00 income · posted Jan 20, 2026

Official filing document

 Bills named in this filing 9
  • S 43
    Skinny Labels, Big Savings Act
  • HR 6485
    Skinny Labels, Big Savings Act
  • S 1302
    Increasing Transparency in Generic Drug Applications Act
  • HR 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S 355
    FDA Modernization Act 3.0
  • HR 2821
    FDA Modernization Act 3.0
  • S 1414
    Expedited Access to Biosimilars Act
  • S 1071
    National Defense Authorization Act for Fiscal Year 2026
  • HR 3838
    Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
 Lobbying activity 2
Copyright/Patent/Trademark

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843).

Health Issues

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem